This phase I trial will involve infusion of donor blood or marrow cells in patients with Acute Myeloid Leukaemia (AML), following consolidation chemotherapy.
This trial is treating patients with Acute Myeloid Leukaemia.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation
Other Non-Commercial Sponsor
University of Sydney
A phase 1 study of infusion of partially HLA matched unrelated donor blood or marrow cells (microtransplantation) following consolidation chemotherapy in patients with AML that are not suitable for allogenic stem cell transplantation.
To determine the safety and tolerability of co-administration of partially HLA antigen matched unrelated donor cryopreserved donor lymphocytes (microtransplantation) with chemotherapy for patients with high risk acute myeloid leukaemia ineligible or unsuitable for high dose chemotherapy and stem cell transplantation.
Recruiting Hospitals Read More